Monte Rosa Therapeutics (GLUE) Cash from Operations (2020 - 2026)

Monte Rosa Therapeutics' Cash from Operations history runs 7 years deep, the most recent figure standing at 37369000.0 for Q1 2026.

• In Q1 2026, Cash from Operations rose 17.86% year-over-year to 37369000.0; the TTM figure through Mar 2026 stood at 14675000.0 (down 142.33% YoY), while the FY2025 annual figure was 22798000.0, down 154.29% from the prior year.
• Cash from Operations was 37369000.0 for Q1 2026 at Monte Rosa Therapeutics, up from 43014000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 128922000.0 in Q4 2024 to a low of 45492000.0 in Q1 2025.
• Historically, Cash from Operations has averaged 9084647.06 across 5 years, with a median of 24706000.0 in 2023.
• Biggest YoY gain for Cash from Operations was 578.37% in 2025; the steepest drop was 133.36% in 2025.
• A 5-year view of Cash from Operations shows it stood at 23961000.0 in 2022, then soared by 223.68% to 29634000.0 in 2023, then jumped by 335.05% to 128922000.0 in 2024, then sank by 133.36% to 43014000.0 in 2025, then advanced by 13.12% to 37369000.0 in 2026.
• The last three Cash from Operations figures came in at 37369000.0 (Q1 2026), 43014000.0 (Q4 2025), and 100428000.0 (Q3 2025), per Business Quant data.